A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2

Takao Tsuji, Takeshi Shimizu, Keiko Sasaki, Kentaro Tsukamoto, Hideyuki Arimitsu, Sadayuki Ochi, Toshiyasu Shimizu, Koki Taniguchi, Masatoshi Noda, Paola Neri, Hiroshi Mori

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Enterohemorrhagic Escherichia coli (EHEC) produces Stx1 and Stx2 causing severe diseases. Their B-subunits (StxBs) exhibit low immunogenicity and the anti-StxB antibodies neutralizing both Stxs has not been prepared yet. By intranasal vaccination with His-tagged-StxB (Stx1B-His or Stx2B-His) plus a mutant heat-labile enterotoxin (mLT) in mice, their serum and lung fluid reacted with appropriate StxB. Mice vaccinated with Stx2B-His plus mLT had antibodies reacting Stx1B and showed the resistance to toxemia of Stx1 and Stx2. This is the first demonstration to get anti-Stx2B serum neutralizing both Stxs. These suggest that the nasal vaccination with Stx2B-His and mLT is effective for preventing toxemias by EHEC.

Original languageEnglish
Pages (from-to)2092-2099
Number of pages8
JournalVaccine
Volume26
Issue number17
DOIs
Publication statusPublished - 16-04-2008

Fingerprint

Shiga Toxin 1
Shiga Toxin 2
Shiga-like toxin 1
toxemia
Shiga-like toxin 2
Cross Protection
Enterohemorrhagic Escherichia coli
Toxemia
enterohemorrhagic Escherichia coli
Nose
Vaccination
Vaccines
chemical derivatives
vaccination
vaccines
Enterotoxins
mice
enterotoxins
blood serum
Serum

All Science Journal Classification (ASJC) codes

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Tsuji, Takao ; Shimizu, Takeshi ; Sasaki, Keiko ; Tsukamoto, Kentaro ; Arimitsu, Hideyuki ; Ochi, Sadayuki ; Shimizu, Toshiyasu ; Taniguchi, Koki ; Noda, Masatoshi ; Neri, Paola ; Mori, Hiroshi. / A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2. In: Vaccine. 2008 ; Vol. 26, No. 17. pp. 2092-2099.
@article{da14b9522e9a44208ac9fd04662af923,
title = "A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2",
abstract = "Enterohemorrhagic Escherichia coli (EHEC) produces Stx1 and Stx2 causing severe diseases. Their B-subunits (StxBs) exhibit low immunogenicity and the anti-StxB antibodies neutralizing both Stxs has not been prepared yet. By intranasal vaccination with His-tagged-StxB (Stx1B-His or Stx2B-His) plus a mutant heat-labile enterotoxin (mLT) in mice, their serum and lung fluid reacted with appropriate StxB. Mice vaccinated with Stx2B-His plus mLT had antibodies reacting Stx1B and showed the resistance to toxemia of Stx1 and Stx2. This is the first demonstration to get anti-Stx2B serum neutralizing both Stxs. These suggest that the nasal vaccination with Stx2B-His and mLT is effective for preventing toxemias by EHEC.",
author = "Takao Tsuji and Takeshi Shimizu and Keiko Sasaki and Kentaro Tsukamoto and Hideyuki Arimitsu and Sadayuki Ochi and Toshiyasu Shimizu and Koki Taniguchi and Masatoshi Noda and Paola Neri and Hiroshi Mori",
year = "2008",
month = "4",
day = "16",
doi = "10.1016/j.vaccine.2008.02.034",
language = "English",
volume = "26",
pages = "2092--2099",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "17",

}

Tsuji, T, Shimizu, T, Sasaki, K, Tsukamoto, K, Arimitsu, H, Ochi, S, Shimizu, T, Taniguchi, K, Noda, M, Neri, P & Mori, H 2008, 'A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2', Vaccine, vol. 26, no. 17, pp. 2092-2099. https://doi.org/10.1016/j.vaccine.2008.02.034

A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2. / Tsuji, Takao; Shimizu, Takeshi; Sasaki, Keiko; Tsukamoto, Kentaro; Arimitsu, Hideyuki; Ochi, Sadayuki; Shimizu, Toshiyasu; Taniguchi, Koki; Noda, Masatoshi; Neri, Paola; Mori, Hiroshi.

In: Vaccine, Vol. 26, No. 17, 16.04.2008, p. 2092-2099.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2

AU - Tsuji, Takao

AU - Shimizu, Takeshi

AU - Sasaki, Keiko

AU - Tsukamoto, Kentaro

AU - Arimitsu, Hideyuki

AU - Ochi, Sadayuki

AU - Shimizu, Toshiyasu

AU - Taniguchi, Koki

AU - Noda, Masatoshi

AU - Neri, Paola

AU - Mori, Hiroshi

PY - 2008/4/16

Y1 - 2008/4/16

N2 - Enterohemorrhagic Escherichia coli (EHEC) produces Stx1 and Stx2 causing severe diseases. Their B-subunits (StxBs) exhibit low immunogenicity and the anti-StxB antibodies neutralizing both Stxs has not been prepared yet. By intranasal vaccination with His-tagged-StxB (Stx1B-His or Stx2B-His) plus a mutant heat-labile enterotoxin (mLT) in mice, their serum and lung fluid reacted with appropriate StxB. Mice vaccinated with Stx2B-His plus mLT had antibodies reacting Stx1B and showed the resistance to toxemia of Stx1 and Stx2. This is the first demonstration to get anti-Stx2B serum neutralizing both Stxs. These suggest that the nasal vaccination with Stx2B-His and mLT is effective for preventing toxemias by EHEC.

AB - Enterohemorrhagic Escherichia coli (EHEC) produces Stx1 and Stx2 causing severe diseases. Their B-subunits (StxBs) exhibit low immunogenicity and the anti-StxB antibodies neutralizing both Stxs has not been prepared yet. By intranasal vaccination with His-tagged-StxB (Stx1B-His or Stx2B-His) plus a mutant heat-labile enterotoxin (mLT) in mice, their serum and lung fluid reacted with appropriate StxB. Mice vaccinated with Stx2B-His plus mLT had antibodies reacting Stx1B and showed the resistance to toxemia of Stx1 and Stx2. This is the first demonstration to get anti-Stx2B serum neutralizing both Stxs. These suggest that the nasal vaccination with Stx2B-His and mLT is effective for preventing toxemias by EHEC.

UR - http://www.scopus.com/inward/record.url?scp=41549158210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549158210&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.02.034

DO - 10.1016/j.vaccine.2008.02.034

M3 - Article

VL - 26

SP - 2092

EP - 2099

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 17

ER -